Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SANAM LOGHAVI and XIAOPING SU.
SANAM LOGHAVI
Connection Strength
0.219
XIAOPING SU
  1. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2024 Nov 19.
    View in: PubMed
    Score: 0.062
  2. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024 05 16; 143(20):2059-2072.
    View in: PubMed
    Score: 0.060
  3. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 04 13; 13(1):53.
    View in: PubMed
    Score: 0.056
  4. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.